BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 27022049)

  • 1. Response to the Letter Regarding Article, "Bringing Back Targets to 'IMPROVE' Atherosclerotic Cardiovascular Disease Outcomes: The Duel for Dual Goals; Are Two Targets Better Than One?".
    Michos ED; Martin SS; Blumenthal RS
    Circulation; 2016 Mar; 133(13):e462. PubMed ID: 27022049
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter by Robinson Regarding Articles, "Bringing Back Targets to 'IMPROVE' Atherosclerotic Cardiovascular Disease Outcomes: The Duel for Dual Goals; Are Two Targets Better Than One?" and "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT".
    Robinson JG
    Circulation; 2016 Mar; 133(13):e461. PubMed ID: 27022048
    [No Abstract]   [Full Text] [Related]  

  • 3. Bringing back targets to "IMPROVE" atherosclerotic cardiovascular disease outcomes: the duel for dual goals; are two targets better than one?
    Michos ED; Martin SS; Blumenthal RS
    Circulation; 2015 Sep; 132(13):1218-20. PubMed ID: 26330413
    [No Abstract]   [Full Text] [Related]  

  • 4. Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT".
    Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White J; Tershakovec AM; Blazing MA; Braunwald E
    Circulation; 2016 Mar; 133(13):e463. PubMed ID: 27022050
    [No Abstract]   [Full Text] [Related]  

  • 5. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
    Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White JA; Tershakovec AM; Blazing MA; Braunwald E
    Circulation; 2015 Sep; 132(13):1224-33. PubMed ID: 26330412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
    J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
    Lancellotti P; Pierard LA; Scheen AJ
    Rev Med Liege; 2015 Sep; 70(9):450-5. PubMed ID: 26638446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes.
    Li L; Zhang M; Su F; Li Y; Shen Y; Shen J; Zhang D
    Lipids Health Dis; 2015 Feb; 14():10. PubMed ID: 25879728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of ezetimibe in secondary cardiovascular prevention finally determined?].
    Lanzi D; Fumeaux T
    Rev Med Suisse; 2015 Nov; 11(496):2257. PubMed ID: 26742360
    [No Abstract]   [Full Text] [Related]  

  • 10. Ezetimibe-Statin Combination to Reduce Cardiovascular Events: The Evidence Base.
    Jialal I; Abate N
    Metab Syndr Relat Disord; 2015 Oct; 13(8):327-8. PubMed ID: 26177147
    [No Abstract]   [Full Text] [Related]  

  • 11. Ezetimibe provides incremental reduction in risk for cardiovascular events and need for revascularisation following an acute coronary syndrome.
    Toth PP
    Evid Based Med; 2015 Oct; 20(5):176. PubMed ID: 26261287
    [No Abstract]   [Full Text] [Related]  

  • 12. Ezetimibe plus a Statin after Acute Coronary Syndromes.
    Singh JS; Struthers AD; Lang CC
    N Engl J Med; 2015 Oct; 373(15):1476. PubMed ID: 26444741
    [No Abstract]   [Full Text] [Related]  

  • 13. Ezetimibe plus a Statin after Acute Coronary Syndromes.
    Richard T; Lelubre C; Vanhaeverbeek M
    N Engl J Med; 2015 Oct; 373(15):1475-6. PubMed ID: 26444740
    [No Abstract]   [Full Text] [Related]  

  • 14. Ezetimibe plus a Statin after Acute Coronary Syndromes.
    Nunes JP
    N Engl J Med; 2015 Oct; 373(15):1475. PubMed ID: 26444739
    [No Abstract]   [Full Text] [Related]  

  • 15. Ezetimibe plus a Statin after Acute Coronary Syndromes.
    Patti G; Cavallari I
    N Engl J Med; 2015 Oct; 373(15):1474-5. PubMed ID: 26444738
    [No Abstract]   [Full Text] [Related]  

  • 16. Ezetimibe plus a Statin after Acute Coronary Syndromes.
    Egom EE
    N Engl J Med; 2015 Oct; 373(15):1474. PubMed ID: 26444737
    [No Abstract]   [Full Text] [Related]  

  • 17. Ezetimibe plus a Statin after Acute Coronary Syndromes.
    Couture P; Durand M; Laskine M
    N Engl J Med; 2015 Oct; 373(15):1473-4. PubMed ID: 26444736
    [No Abstract]   [Full Text] [Related]  

  • 18. Ezetimibe plus a Statin after Acute Coronary Syndromes.
    Silbernagel G; Baumgartner I; März W
    N Engl J Med; 2015 Oct; 373(15):1473. PubMed ID: 26444735
    [No Abstract]   [Full Text] [Related]  

  • 19. Ezetimibe plus a Statin after Acute Coronary Syndromes.
    Cannon CP; Blazing MA; Braunwald E
    N Engl J Med; 2015 Oct; 373(15):1476-7. PubMed ID: 26444734
    [No Abstract]   [Full Text] [Related]  

  • 20. Did we IMPROVE-IT: thoughts on LDL targeting post-trial?
    Packard C; Stezhka T
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):465-6. PubMed ID: 25865021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.